A seven-gene signature aggregates a subgroup of stage II colon cancers with stage III

OMICS A Journal of Integrative Biology

Volumn 16, Issue 10, 2012, Pages 560-565

  Laibe, Sophy ^a   Lagarde, Arnaud ^a   Ferrari, Anthony ^b   Monges, Geneviève ^a,b,c   Birnbaum, Daniel ^a,b   Olschwang, Sylviane ^b,d  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL FEATURE; COLON CARCINOMA; DISEASE SEVERITY; DNA MICROARRAY; EEF1D GENE; EME1 GENE; FEMALE; FKBP8 GENE; GENE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; PRIORITY JOURNAL; RAB11B GENE; RPL14 GENE; RPL23A GENE; RPL27A GENE; RPL38 GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSCRIPTOME; YOUNG ADULT;

EID: 84867046113     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2012.0039     Document Type: Article

References (25)

1. Avruch, J., Long, X., Ortiz-Vega, S., Rapley, J., Papageorgiou, A., and Dai, N. (2009). Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab 296, E592-E602.
2. Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc 57, 289-300.
3. Benson, A.B. 3rd, Schrag, D., Somerfield, M.R., et al. (2004). American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22, 3408-3419.
4. Bertucci, F., Finetti, P., Cervera, N., et al. (2006). Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66, 4636-4644.
5. Brosens, R.P., Belt, E.J., Haan, J.C., et al. (2011). Deletion of chromosome 4q predicts outcome in stage II colon cancer patients. Cell Oncol (Dordr) 34, 215-223.
6. Choi, B.H., and Yoon, H.S. (2011). FKBP38-Bcl-2 interaction: a novel link to chemoresistance. Curr Opin Pharmacol 11, 354-359.
7. Duncan, R., Carpenter, B., Main, L.C., Telfer, C., and Murray, G.I. (2008). Characterization and protein expression profiling of annexins in colorectal cancer. Br J Cancer 98, 426-433.
8. Ein-Dor, L., Kela, I., Getz, G., Vol, D., and Domany, E. (2005). Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21, 171-178.
9. Fishel, I., Kaufman, A., and Ruppin, E. (2007). Meta-analysis of gene expression data: a predictor-based approach. Bioinformatics 23, 1599-1606.
10. Forment, J.V., Blasius, M., Guerini, I., and Jackson, S.P. (2011). Structure-specific DNA endonuclease Mus81/Eme1 generates DNA damage caused by Chk1 inactivation. PLoS One 6, e23517.
11. Hartigan, J.A., and Wong, M.A. (1979). A K-means clustering algorithm. Applied Statistics 28, 100-108.
12. Irizarry, R.A., Hobbs, B., Collin, F., et al. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264.
13. Kelley, R.K., and Venook, A.P. (2011). Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer 10, 73-80.
14. Kopecka, J., Campia, I., Brusa, D., et al. (2011). Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. J Cell Mol Med 15, 1492-1504.
15. O'Dwyer, D., Ralton, L.D., O'Shea, A. and Murray, G.I. (2011). The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS One 6, e27718.
16. Petersen, V.C., Baxter, K.J., Love, S.B., and Shepherd, N.A. (2002). Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 51, 65-69.
17. Pistollato, F., Rampazzo, E., Abbadi, S., et al. (2009). Molecular mechanisms of HIF-1alpha modulation induced by oxygen tension and BMP2 in glioblastoma derived cells. PLoS One 4, e6206.
18. Rodrigues-Lisoni, F.C., Peitl, P. Jr., Vidotto, A., et al. (2010). Genomics and proteomics approaches to the study of cancerstroma interactions. BMC Med Genomics 3, 14.
19. Salazar, R., Roepman, P., Capella, G., et al. (2011). Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29, 17-24.
20. Sargent, D.J., Marsoni, S., Monges, G., et al. (2010). Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28, 3219-3226.
21. Smyth, G.K. (2004). Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3, Article 3.
22. Tomoda, Y., Katsura, M., Okajima, M., Hosoya, N., Kohno, N., and Miyagawa, K. (2009). Functional evidence for Eme1 as a marker of cisplatin resistance. Int J Cancer 124, 2997-3001.
23. Van Schaeybroeck, S., Allen, W.L., Turkington, R.C., and Johnston, P.G. (2011). Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol 8, 222-232.
24. Ward, J. (1963). Hierarchical grouping to optimize an objective function. J Am Stat Assn 58, 236-244.
25. Wu, Z., Irizarry, R.A., Gentleman, R., Martinez-Murillo, F., and Spencer, F. (2004). A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 99, 909-917.